ASO Author Reflections: Patient-Reported Outcomes—Bench to Bedside

  • Srinivas Joga IvaturyEmail author
  • Sandra L. Wong
  • Deborah Schrag
ASO Author Reflections



Funded by NIH UM1 CA233080-1.


Dr. Schrag has received research funding from Pfizer. She also has received remuneration from GRAIL and from JAMA for editorial services. Drs. Ivatury and Wong report no conflicts of interest.


  1. 1.
    Basch E, Reeve BB, Mitchell SA, et al. Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst. 2014;106(9):244.CrossRefGoogle Scholar
  2. 2.
    Basch E, Dueck AC, Rogak LJ, et al. Feasibility of implementing the patient-reported outcomes version of the common terminology criteria for adverse events in a multicenter trial: NCCTG N1048. J Clin Oncol. 2018;36(31):3120–5.CrossRefGoogle Scholar
  3. 3.
    Ivatury SJ, Hazard-Jenkins HW, Brooks GA, et al. Translation of patient-reported outcomes in oncology clinical trials to everyday practice. Ann Surg Oncol. 2019. Scholar
  4. 4.
    McCann L, Maguire R, Miller M, Kearney N. Patients’ perceptions and experiences of using a mobile phone-based advanced symptom management system (ASyMS©) to monitor and manage chemotherapy related toxicity. Eur J Cancer Care. 2009;18(2):156–64.CrossRefGoogle Scholar
  5. 5.
    Electronic Patient Reporting of Symptoms During Cancer Treatment (PRO-TECT). National Institutes of Health Clinical Accessed 8 July 2019.
  6. 6.
    Improving the Management of Symptoms During and Following Cancer Treatment (IMPACT). National Cancer Institute: Division of Cancer Control and Population Sciences. Accessed 8 July 2019.

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  • Srinivas Joga Ivatury
    • 1
    • 2
    Email author
  • Sandra L. Wong
    • 1
    • 2
  • Deborah Schrag
    • 3
  1. 1.Department of SurgeryDartmouth-Hitchcock Medical CenterLebanonUSA
  2. 2.Geisel School of MedicineLebanonUSA
  3. 3.Dana-Farber Cancer InstituteBostonUSA

Personalised recommendations